Franca Formichelli

Learn More
After two studies reporting response rates higher than 70% in HER2-positive metastatic breast cancer with weekly trastuzumab and vinorelbine, we planned a phase 2 study to test activity of the same combination, with trastuzumab given every 3 weeks. Patients with HER2-positive metastatic breast cancer (3+ at immunohistochemistry or positive at fluorescence(More)
  • 1